Indication
Metastatic Malignant Solid Neoplasm
90 clinical trials
106 products
29 drugs
Clinical trial
An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Product
NavitoclaxProduct
TrametinibClinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-07
Product
BerzosertibProduct
IrinotecanClinical trial
Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]Status: Completed, Estimated PCD: 2021-10-04
Product
TLR9 Agonist SD-101Clinical trial
Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)Status: Recruiting, Estimated PCD: 2025-09-03
Product
AxitinibProduct
CrizotinibProduct
PalbociclibProduct
TalazoparibClinical trial
Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 ExpressionStatus: Not yet recruiting, Estimated PCD: 2026-03-31
Product
AzenosertibClinical trial
Phase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Product
ZEN-3694Product
IpilimumabProduct
Trastuzumab DeruxtecanClinical trial
Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2025-08-31
Product
IpatasertibClinical trial
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation TherapyStatus: Active (not recruiting), Estimated PCD: 2022-06-07
Drug
RivaroxabanDrug
TiragolumabProduct
NivolumabClinical trial
A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Product
ImatinibClinical trial
Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment TrialStatus: , Estimated PCD: 2025-07-01
Product
NilotinibClinical trial
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesStatus: Completed, Estimated PCD: 2023-11-30
Drug
AbexinostatProduct
PembrolizumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideClinical trial
Preoperative Radiosurgery for Brain Metastases Planned for Surgical Resection: A Two Arm Pilot StudyStatus: Recruiting, Estimated PCD: 2025-01-31
Product
DexamethasoneProduct
Neoantigen Peptide VaccineClinical trial
A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in NSCLC Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) ExpressionStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
CeritinibProduct
EverolimusClinical trial
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial MetastasesStatus: Completed, Estimated PCD: 2023-12-08
Product
Bintrafusp AlfaProduct
PimasertibClinical trial
A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2025-12-31
Product
PanitumumabProduct
SotorasibClinical trial
A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic AlterationsStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
InfigratinibClinical trial
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB)Status: Active (not recruiting), Estimated PCD: 2024-09-11
Product
AvelumabClinical trial
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ TumorsStatus: Active (not recruiting), Estimated PCD: 2022-11-30
Product
SorafenibDrug
AdavosertibClinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-31
Drug
CeralasertibProduct
OlaparibClinical trial
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant NeoplasmStatus: Active (not recruiting), Estimated PCD: 2023-10-04
Product
Antiretroviral TherapyClinical trial
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-03
Product
AvapritinibProduct
DurvalumabClinical trial
A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774Status: Recruiting, Estimated PCD: 2025-01-31
Product
TMZProduct
TuvusertibClinical trial
A Phase 1 Study of the Polymerase Theta (POLQ) Inhibitor Novobiocin in BRCA-Mutant and Other DNA Damage Repair-Deficient Solid TumorsStatus: Recruiting, Estimated PCD: 2024-05-31
Product
NovobiocinClinical trial
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive TumorsStatus: Recruiting, Estimated PCD: 2025-11-11
Product
LarotrectinibClinical trial
A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2020-02-20
Product
IbrutinibClinical trial
Phase I Sequential Trial of Agents Against DNA Repair (STAR)Status: Active (not recruiting), Estimated PCD: 2023-02-22
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-07-01
Drug
T-VECClinical trial
Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid TumorsStatus: Withdrawn, Estimated PCD: 2026-11-08
Clinical trial
Levorphanol as a Second Line Opioid in Cancer Patients Undergoing Opioid Rotation: An Open Label StudyStatus: Completed, Estimated PCD: 2023-06-15
Product
HydrocodoneProduct
HydromorphoneProduct
LevorphanolProduct
MorphineProduct
OxycodoneProduct
OxymorphoneClinical trial
Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)Status: Not yet recruiting, Estimated PCD: 2024-10-31
Product
Enfortumab VedotinProduct
Sacituzumab GovitecanClinical trial
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and LymphomasStatus: Withdrawn, Estimated PCD: 2021-07-12
Product
P97 Inhibitor CB-5339Clinical trial
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid TumorsStatus: Terminated, Estimated PCD: 2021-07-28
Product
VistusertibClinical trial
A Phase I Study of Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-11-22
Product
Nab-paclitaxel/DanburstotugClinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
AbemaciclibClinical trial
A Phase 1 Study of ZEN003694 in Combination With Binimetinib in Solid Tumors With RAS Pathway Alterations and Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-03-14
Product
BinimetinibClinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2021-06-29
Product
SapanisertibProduct
Ziv-AfliberceptProduct
AbirateroneClinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Product
CabozantinibProduct
AfatinibClinical trial
Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-10-15
Drug
AtezolizumabClinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)Status: Recruiting, Estimated PCD: 2030-07-01
Drug
AlpelisibClinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Product
Enzyme InhibitorProduct
BicalutamideClinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
CetuximabProduct
VemurafenibProduct
BortezomibClinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelStatus: Active (not recruiting), Estimated PCD: 2022-07-25
Drug
DocetaxelProduct
AZD8186Drug
fluorouracilDrug
AlpelisibProduct
DabrafenibProduct
CabazitaxelDrug
mFOLFOX6Product
NeratinibProduct
DacomitinibClinical trial
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2019-04-01
Drug
AN0025Drug
UTD1Clinical trial
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor M1774Status: Recruiting, Estimated PCD: 2024-08-31
Product
PeposertibClinical trial
A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
CopanlisibProduct
SelumetinibClinical trial
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2022-12-21
Drug
MetforminDrug
CelecoxibProduct
DasatinibClinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Drug
fludarabineClinical trial
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and IpilimumabStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
CobimetinibProduct
DarolutamideClinical trial
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing CancerStatus: Terminated, Estimated PCD: 2022-08-04
Product
PD1 InhibitorDrug
R-CHOPClinical trial
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma PatientsStatus: Not yet recruiting, Estimated PCD: 2024-05-31
Product
TAK-243Product
EnasidenibDrug
EntrectinibProduct
EnzalutamideDrug
ErlotinibClinical trial
A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-04-01
Product
AxatilimabProduct
RetifanlimabClinical trial
Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-08-29
Product
BMS-986156Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-07-01
Product
SonidegibClinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Product
UprosertibClinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
doxorubicinClinical trial
Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
IvuxolimabProduct
UtomilumabClinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Product
ElimusertibProduct
TopotecanClinical trial
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
olaparibClinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor CemiplimabStatus: Terminated, Estimated PCD: 2022-12-02
Product
CemiplimabClinical trial
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-01-13
Product
VeliparibDrug
FOLFOXIRIClinical trial
A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerStatus: Active (not recruiting), Estimated PCD: 2024-04-08
Product
PsilocybinProduct
PemetrexedDrug
SelinexorClinical trial
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced CancerStatus: Active (not recruiting), Estimated PCD: 2019-12-27
Product
AnamorelinClinical trial
A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant TumorsStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Product
TelaglenastatClinical trial
Genomically-Guided Treatment Trial in Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-10-01
Product
PaxalisibClinical trial
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Edodekin alfaDrug
AdagrasibClinical trial
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-05-27
Product
BMS-986218Clinical trial
Phase I Trial of ZEN003694 (ZEN-3694) in Combination With Capecitabine in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerStatus: Completed, Estimated PCD: 2020-07-29
Clinical trial
A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive TherapyStatus: Active (not recruiting), Estimated PCD: 2023-08-01
Product
M7824Product
OnalespibClinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
ALRN-6924Clinical trial
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) CarcinomasStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
LurbinectedinDrug
ValemetostatClinical trial
A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive AdenocarcinomasStatus: Recruiting, Estimated PCD: 2026-01-01
Product
Antineoplastic VaccineDrug
GM-CSFClinical trial
A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing MalignanciesStatus: , Estimated PCD: 2024-06-30
Clinical trial
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic DysfunctionStatus: Active (not recruiting), Estimated PCD: 2023-08-04
Clinical trial
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-08-15
Product
AT7519Clinical trial
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31